Peptides are where clinic demand and regulatory uncertainty overlap most. Products such as BPC-157 and TB-500 are widely requested, widely sold as "research chemicals," and, until 2026, were on the FDA's list of substances that pharmacies could not compound. Two developments this year changed the picture without settling it. This guide explains the framework, what changed, and how clinics source peptides through licensed pharmacies on ScriptLinkRx instead of gray-market sellers.
How a peptide becomes compoundable
A 503A compounding pharmacy may only use a bulk drug substance that meets one of three tests:
- It complies with a USP or NF monograph.
- It is a component of an FDA-approved drug.
- It appears on the 503A bulks list that the FDA is building through its Pharmacy Compounding Advisory Committee (PCAC) and rulemaking.
Because the list is still being written, the FDA runs an interim policy for nominated substances. Category 1 substances may be used pending rulemaking. Category 2 substances, those the FDA identified as raising significant safety risks, may not. Category 3 substances lack enough information and may not be used either. Most of the peptides clinics ask about were nominated and, in 2023, placed in Category 2.
Separately, where an approved product contains the same peptide, the "essentially a copy" restriction applies. Bremelanotide (PT-141) is the clearest example: it is a component of an approved drug, so a 503A pharmacy may compound it only where the prescriber documents a significant difference for the patient and the pharmacy does not do so regularly or in inordinate amounts.
What changed in 2026
April 2026: removal from Category 2. On April 15, 2026 the FDA removed a group of peptides, including BPC-157, TB-500 and injectable GHK-Cu, from Category 2 of the interim list. That was a procedural step: it moved those substances out of the "significant safety risk" category ahead of committee review. It did not place them in Category 1, approve them, or authorize compounding.
July 2026: the PCAC votes. At its July 23–24, 2026 meeting the committee reviewed seven peptides and voted to recommend six for the 503A bulks list: BPC-157, KPV and TB-500 (8 to 6 each), MOTS-c (7 to 5), Semax and Epitalon. It did not recommend DSIP. FDA career staff had recommended against all seven. The votes are advisory. Adding a substance to the list requires FDA rulemaking, and no final listing had been published as of October 2026. Injectable GHK-Cu is expected to come before the committee in 2027.
The practical state of play for a clinic: BPC-157 and TB-500 are closer to a lawful pathway than they were in 2025, but they are not there yet. Pharmacies differ in how they read the interim position, and state boards have their own views. Prescribers should verify current status with the dispensing pharmacy and their state board before prescribing.
Peptides with a clearer pathway
- Sermorelin has appeared in Category 1 of the interim 503A list and had a previously approved branded product that was withdrawn for commercial, not safety, reasons. Compounded sermorelin is available from partner pharmacies under the interim policy. See the sermorelin provider guide.
- Bremelanotide (PT-141) is compoundable as a component of an approved drug, subject to the essentially-a-copy rules described above. See the PT-141 provider guide.
- Topical GHK-Cu sits in a different regulatory lane from the injectable form; the GHK-Cu guide explains the split.
Research chemicals are not an alternative
Clinics under pressure to offer a peptide sometimes look at online sellers shipping vials labeled "for research use only." Those products are not pharmaceuticals. They are not made under drug manufacturing standards, not reviewed by the FDA, not tested by a pharmacy, and not dispensed on a prescription. The label does not protect the clinic once the product is administered to a patient: the FDA has treated such products as unapproved and misbranded drugs, and state boards have disciplined prescribers for using them. Retatrutide, which has no approval and no compounding pathway, is the most prominent example; the retatrutide regulatory status guide covers it.
How peptide sourcing works on ScriptLinkRx
ScriptLinkRx is an ordering platform in front of licensed compounding pharmacies, which means the pharmacies, not the platform, decide what is compounded:
- Partner 503A pharmacies list the peptides they prepare, in which forms, at what price, and the states they are licensed to ship to. Availability varies by pharmacy and changes as the FDA's position moves.
- The prescriber selects the patient, writes the prescription with patient-specific directions, and signs it. ScriptLinkRx does not recommend or pre-select products.
- The catalog only shows a patient what can lawfully ship to their state.
- Order and prescription records stay with the patient and the practice for board or FDA inquiries.
Because status is still moving, every peptide guide on this site carries a "regulatory information current as of" date. Check it, and check the pharmacy's current position, before prescribing.
Sources
- FDA: Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
- FDA: Pharmacy Compounding Advisory Committee
- FDA: Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A (guidance)
- McDermott Will & Emery: PCAC backs majority of peptides in two-day public meeting (July 2026)
- NCPA: FDA advisory committee nominates six peptides for pharmacies to compound (July 31, 2026)